Detalles de la búsqueda
1.
Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe.
BMC Cancer
; 15: 787, 2015 Oct 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-26498283
2.
A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer.
BMC Med
; 12: 93, 2014 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24898705
3.
Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
Oncologist
; 18(1): 46-53, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23263288
4.
Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
Curr Med Res Opin
; 30(6): 1007-16, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24490834
5.
Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Chest
; 143(4): 955-962, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23187897
6.
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
Ann N Y Acad Sci
; 1291: 14-32, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23659703
Resultados
1 -
6
de 6
1
Próxima >
>>